Lancashire and South Cumbria
Formulary
Formulary
9 Nutrition and blood
09-01-01-02 Parenteral iron
Prescribe parenteral iron products by brand name - important differences between formulations.
| Ferric Carboxymaltose Ferinject® |
|
Formulary
|
Injection 50mg/mL First line choice. Follow Trust protocols. For use in patients with asthma or eczema. |
 MHRA: Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures |
|
| Ferric Derisomaltose Diafer® |
|
Formulary
|
Injection 50mg/mL (2mL ampoule) Follow Trust protocols. For use by renal unit only. |
|
MHRA: Monofer 100mg/ml solution for injection/infusion▼ and Diafer 50mg/ml solution for injection▼: name change from iron isomaltoside to ferric derisomaltose |
|
|
| Iron Sucrose Venofer® |
|
Formulary
|
Injection 100mg/5mL Second line choice. Follow Trust protocols. For intravenous use only. Do not use in patients with asthma or eczema. |
|
|
Links
- EMC: Manufacturers Summary of Product Characteristics (SPC)
Ferinject prescription sheet UHMB- Ideal body weight calculator
- LSCMMG: Bariatric surgery guidelines for prescribing of vitamins and nutritional supplements: Position Statement
- LSCMMG: Gluten-Free food products: Position Statement
- LSCMMG: Oral Nutritional Supplements in Primary Care
- LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children
- MHRA Drug Safety Update Nov 2020: Ferric carboxymaltose (Ferinject): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures
- MHRA: Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures
- MHRA: Intravenous iron and serious hypersensitivity reactions: new strengthened recommendations to manage and minimise risk (August 2013)
- MHRA: Monofer 100mg/ml solution for injection/infusion▼ and Diafer 50mg/ml solution for injection▼: name change from iron isomaltoside to ferric derisomaltose
- MHRA: Serious hypersensitivity reactions—contraindicated if any drug allergy (Sept 14)
- NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
- NICE NG20: Coeliac disease: recognition, assessment and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease
- UKMI Q&A: Guidance on administration of Cosmofer
- Venofer prescription sheet UHMB